Compare AUDC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | ALXO |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 240.8M |
| IPO Year | 2000 | 2020 |
| Metric | AUDC | ALXO |
|---|---|---|
| Price | $8.88 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.50 | $3.50 |
| AVG Volume (30 Days) | 77.1K | ★ 913.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $0.41 |
| 52 Week High | $11.48 | $2.66 |
| Indicator | AUDC | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 40.00 |
| Support Level | $8.78 | $1.41 |
| Resistance Level | $9.19 | $1.90 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 58.17 | 29.37 |
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.